OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
4.390
-0.070 (-1.57%)
Mar 31, 2025, 10:47 AM EDT - Market open

Company Description

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.

Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer.

The company is headquartered in Boulder, Colorado.

OnKure Therapeutics, Inc.
OnKure Therapeutics logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Nicholas Saccomano

Contact Details

Address:
6707 Winchester Circle, Suite 400
Boulder, Colorado 80301
United States
Phone 720 307 2892
Website onkuretherapeutics.com

Stock Details

Ticker Symbol OKUR
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001637715
ISIN Number US68277Q1058
Employer ID 47-2309515
SIC Code 2834

Key Executives

Name Position
Dr. Nicholas A. Saccomano Ph.D. President, Chief Executive Officer and Director
Jason A. Leverone CPA Chief Financial Officer
Dr. Samuel Agresta M.D., M.P.H. Chief Medical Officer
Dr. Dylan Hartley Ph.D. Chief Scientific Officer
Rogan P. Nunn J.D. General Counsel and Secretary
Dr. James Blake Ph.D. Senior Vice President of Computational Drug Discovery
Dr. Duncan Walker Ph.D. Chief Development Officer
Dr. Kevin S. Litwiler Ph.D. Senior Vice President of DMPK and Clinical Pharmacology
Dr. Mark L. Boys Ph.D. Senior Vice President of Discovery Chemistry
Roberta Alton Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 24, 2025 424B3 Prospectus
Mar 21, 2025 EFFECT Notice of Effectiveness
Mar 20, 2025 POS AM Post-Effective amendments for registration statement
Mar 10, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 10, 2025 424B3 Prospectus
Mar 10, 2025 8-K Current Report
Mar 10, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Feb 6, 2025 SCHEDULE 13G/A Filing